Our analysis of TCGA datasets revealed that KRAS4A splicing variants are expressed at levels that could potentially influence tumor progression, with some cancer tissues even exhibiting KRAS4A as the dominant splicing variant over KRAS4B. The gene discussed is KRAS; the disease is neoplasm.